Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.
The role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low dose Computed Tomography (LDCT) screening for those...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0306163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595702999416832 |
|---|---|
| author | Francis Michael Sullivan Frances S Mair William Anderson Cindy Chew Alistair Dorward John Haughney Fiona Hogarth Denise Kendrick Roberta Littleford Alex McConnachie Colin McCowan Nicola McMeekin Manish Patel Petra Rauchhaus Fergus Daly Lewis Ritchie John Robertson Joseph Sarvesvaran Herbert Sewell Thomas Taylor Shaun Treweek Kavita Vedhara Stuart Schembri |
| author_facet | Francis Michael Sullivan Frances S Mair William Anderson Cindy Chew Alistair Dorward John Haughney Fiona Hogarth Denise Kendrick Roberta Littleford Alex McConnachie Colin McCowan Nicola McMeekin Manish Patel Petra Rauchhaus Fergus Daly Lewis Ritchie John Robertson Joseph Sarvesvaran Herbert Sewell Thomas Taylor Shaun Treweek Kavita Vedhara Stuart Schembri |
| author_sort | Francis Michael Sullivan |
| collection | DOAJ |
| description | The role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low dose Computed Tomography (LDCT) screening for those at highest risk. We randomized 12 208 individuals aged 50-75 at high risk of developing lung cancer to either the test or to standard clinical care. Outcomes were ascertained from Register of Deaths and Cancer Registry. Cox proportional hazards models were used to estimate the hazard ratio of the rate of deaths from all causes and lung cancer. Additional analyses were performed for cases of lung cancer diagnosed within two years of the initial test. After 5 years 326 lung cancers were detected (2.7% of those enrolled). The total number of deaths reported from all causes in the intervention group was 344 compared to 388 in the control group. There were 73 lung cancer deaths in the intervention arm and 90 in the controls (Adjusted HR 0.789 (0.636, 0.978). An analysis of cases of lung cancer detected within 2 years of randomization in the intervention group showed that there were 34 deaths from all causes and 29 from lung cancer. In the control group there were 56 deaths with 49 from lung cancer. In those diagnosed with lung cancer within 2 years of randomization the hazard ratio for all cause mortality was 0.615 (0.401,0.942) and for lung cancer 0.598 (0.378, 0.946). Further large-scale studies of the role of biomarkers to target lung cancer screening, in addition to LDCT, are likely to provide additional value. |
| format | Article |
| id | doaj-art-a93142c0f00f4a1e88d8a2773f42e034 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-a93142c0f00f4a1e88d8a2773f42e0342025-01-18T05:30:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e030616310.1371/journal.pone.0306163Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.Francis Michael SullivanFrances S MairWilliam AndersonCindy ChewAlistair DorwardJohn HaughneyFiona HogarthDenise KendrickRoberta LittlefordAlex McConnachieColin McCowanNicola McMeekinManish PatelPetra RauchhausFergus DalyLewis RitchieJohn RobertsonJoseph SarvesvaranHerbert SewellThomas TaylorShaun TreweekKavita VedharaStuart SchembriThe role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low dose Computed Tomography (LDCT) screening for those at highest risk. We randomized 12 208 individuals aged 50-75 at high risk of developing lung cancer to either the test or to standard clinical care. Outcomes were ascertained from Register of Deaths and Cancer Registry. Cox proportional hazards models were used to estimate the hazard ratio of the rate of deaths from all causes and lung cancer. Additional analyses were performed for cases of lung cancer diagnosed within two years of the initial test. After 5 years 326 lung cancers were detected (2.7% of those enrolled). The total number of deaths reported from all causes in the intervention group was 344 compared to 388 in the control group. There were 73 lung cancer deaths in the intervention arm and 90 in the controls (Adjusted HR 0.789 (0.636, 0.978). An analysis of cases of lung cancer detected within 2 years of randomization in the intervention group showed that there were 34 deaths from all causes and 29 from lung cancer. In the control group there were 56 deaths with 49 from lung cancer. In those diagnosed with lung cancer within 2 years of randomization the hazard ratio for all cause mortality was 0.615 (0.401,0.942) and for lung cancer 0.598 (0.378, 0.946). Further large-scale studies of the role of biomarkers to target lung cancer screening, in addition to LDCT, are likely to provide additional value.https://doi.org/10.1371/journal.pone.0306163 |
| spellingShingle | Francis Michael Sullivan Frances S Mair William Anderson Cindy Chew Alistair Dorward John Haughney Fiona Hogarth Denise Kendrick Roberta Littleford Alex McConnachie Colin McCowan Nicola McMeekin Manish Patel Petra Rauchhaus Fergus Daly Lewis Ritchie John Robertson Joseph Sarvesvaran Herbert Sewell Thomas Taylor Shaun Treweek Kavita Vedhara Stuart Schembri Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. PLoS ONE |
| title | Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. |
| title_full | Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. |
| title_fullStr | Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. |
| title_full_unstemmed | Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. |
| title_short | Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. |
| title_sort | five year mortality in an rct of a lung cancer biomarker to select people for low dose ct screening |
| url | https://doi.org/10.1371/journal.pone.0306163 |
| work_keys_str_mv | AT francismichaelsullivan fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT francessmair fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT williamanderson fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT cindychew fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT alistairdorward fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT johnhaughney fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT fionahogarth fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT denisekendrick fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT robertalittleford fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT alexmcconnachie fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT colinmccowan fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT nicolamcmeekin fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT manishpatel fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT petrarauchhaus fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT fergusdaly fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT lewisritchie fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT johnrobertson fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT josephsarvesvaran fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT herbertsewell fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT thomastaylor fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT shauntreweek fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT kavitavedhara fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening AT stuartschembri fiveyearmortalityinanrctofalungcancerbiomarkertoselectpeopleforlowdosectscreening |